By Michael A. Carrier
In this issue CPI includes a special feature on the SmithKline Beecham Corp. v. King Drug Co. of Florence (“King Drug”) case to be decided by the SCOTUS this fall.
In its 2013 decision in FTC v. Actavis, the U.S. Supreme Court held that agreements by which brand-name drug companies pay generic firms to settle patent litigation and delay entering the market could have “significant adverse effects on competition” and violate antitrust laws. Since the decision, courts
...THIS ARTICLE IS NOT AVAILABLE FOR IP ADDRESS 18.222.67.251
Please verify email or join us to access premium content!